Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma.
10.1007/s13238-012-2067-9
- Author:
Yun YANG
1
;
Tian XIA
;
Ning LI
;
Jin ZHANG
;
Yuan YANG
;
Wenming CONG
;
Qiang DENG
;
Ke LAN
;
Weiping ZHOU
Author Information
1. The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
- Publication Type:Journal Article
- MeSH:
Carcinoma, Hepatocellular;
diagnosis;
genetics;
surgery;
virology;
Carrier State;
virology;
Cohort Studies;
Female;
Genetic Predisposition to Disease;
genetics;
Hepatitis B virus;
physiology;
Humans;
Liver Neoplasms;
diagnosis;
genetics;
surgery;
virology;
Male;
Middle Aged;
Neoplasm Staging;
Polymorphism, Single Nucleotide;
Prognosis;
Proto-Oncogene Proteins c-mdm2;
genetics;
Tumor Suppressor Protein p53;
genetics
- From:
Protein & Cell
2013;4(1):71-81
- CountryChina
- Language:English
-
Abstract:
The p53 signaling pathway works as a potent barrier to tumor progression. Two single nucleotide polymorphisms (SNPs) in the gene loci of p53 pathway, p53 codon 72 Arg72Pro and MDM2 SNP309 (T > G), have been shown to cause perturbation of p53 function, but the effect of the two SNPs on the risk of hepatocellular carcinoma (HCC) remains inconsistent. This study investigated the influence of combined p53 Arg72Pro and MDM2 SNP309 on the risk of developing HCC in patients with chronic hepatitis B virus infection, and evaluated the significance of the two combined SNPs on patient prognosis. In total, 350 HCC patients, 230 non-HCC patients, and 96 healthy controls were genotyped for the p53 Arg72Pro and MDM2 SNP309. The combined p53 Pro/Pro and MDM2 G/G genotype was significantly associated with HCC risk (P = 0.047). Multivariate analysis indicated that combined p53 Pro/Pro and MDM2 G/G genotype was an independent factor affecting recurrence and survival (P < 0.05). Patients with combined p53 Pro/Pro and MDM2 G/G genotypes had a poorer prognosis than other genotypes, P < 0.01 for both disease-free survival (DFS) and overall survival (OS). DFS and OS rates also differed significantly between Barcelona Clinic Liver Cancer (BCLC) stage A patients with combined p53 Pro/Pro and MDM2 G/G and other genotypes (P < 0.05). Thus, the combined p53 Pro/Pro and MDM2 G/G genotype is associated with increased risk of developing HCC and is an independent adverse prognostic indicator in early stage HCC.
